Re:$1,000 Hepatitis Pill Shows Why Fixing Health Costs Is So...
by busyant on Monday August 04, 2014 @08:05AM
(#8131322)
Back in 2012 (I think), I thought it was insane that they were willing to pay $11B for Pharmasset based on Phase 2 data.
At the very least, it was a ballsy move that has generated about 6 billion in revenue in just the 1st 6 months on market in the U.S.
Note that Bristol Myers Squibb paid about 2.5Billion to acquire a competing company (Inhibitex) and that drug had to be junked for safety issues shortly after the acquisition.
At the very least, it was a ballsy move that has generated about 6 billion in revenue in just the 1st 6 months on market in the U.S.
Note that Bristol Myers Squibb paid about 2.5Billion to acquire a competing company (Inhibitex) and that drug had to be junked for safety issues shortly after the acquisition.